期刊文献+

不同工艺制备的固体脂质纳米粒系统性能比较研究 被引量:4

A Comparative Study on Properties of SLN Systems Prepared by Different Procedures
下载PDF
导出
摘要 目的:比较不同工艺制备的固体脂质纳米粒系统性能。方法:分别采用长时间高剪切法、长时间探头超声法、单次高剪切超声法和改进的高剪切超声法制备固体脂质纳米粒混悬液,应用激光粒度仪分析仪测定纳米粒粒径及其分布特征,据此评价4种方法制备的固体脂质纳米粒系统性能。结果:与其他3种制备方法比较,改进的高剪切超声法制备的固体脂质纳米粒混悬液粒径分布窄,且呈单模分布,平均粒径约100 nm,具良好的贮存稳定性,4℃下可稳定放置达半年。结论:改进的高剪切超声法可制备出性能优良的稳定的固体脂质纳米粒系统。 Objective: To compare the properties of solid lipid nanoparticles (SLN) systems prepared by different procedures. Methods: The four methods of long time high shear, long time probe ultrasound, once high shear and ultrasound and modified high shear and ultrasound were used respectively to prepare SLN suspensions. Then the properties of particle distribution and particle size of the SLN prepared by the four methods were measured by laser diffraction, which were used to assess their properties. Results: Compared with by the other methods, the SLN suspension with narrow and mono-module particle distribution and mean particle size of about 100 nm was prepared by the modified high shear and ultrasound method. It was stored stably up to a half year at 4℃. Conclusion: The modified method could be used to prepare the stable SLN system with excellent property.
出处 《药学进展》 CAS 2006年第7期322-325,共4页 Progress in Pharmaceutical Sciences
关键词 固体脂质纳米粒 改进的高剪切乳化超声法 平均粒径 粒径分布 Solid lipid nanoparticles Modified high shear and ultrasound method Mean particle size Particle size distribution
  • 相关文献

参考文献14

  • 1Muller R H, Jaeobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future[J]. Adv Drug Del Rev, 2001,47(10) : 3-19.
  • 2Muller R H, Mader K, Gohla S. Solid lipid nanoparticles(SLN) for controlled drug delivery-a review of the state of the art[J]. Eur J Pharm Biopharm, 2000, 50(2) : 161-177.
  • 3Mehnert W, Mader K. Solid lipid nanoparficles production, chametedzation and applications[J]. Adv Drug Del Rev, 2001,47 (7):165-196.
  • 4Muller R H, Maassen S, Schwarz C, et al. Solid lipid nanoparticles (SLN) as potential carder for human use:interaction with human granulocytes [ J ]. J Controlled Release, 1997,47(6) : 261-269.
  • 5Cavalli R, Caputo O, Gasco M R. Preparation and characterization of solid lipid nanospheres containing paclitaxel[J]. Eur J Pharm Sci, 2000,10(3) :305-309.
  • 6Ugazio E, Cavalli R, Gaseo M R. Incorporation of cydosporin A in solid lipid nanoparticles (SLN)[J]. Int J Pharm, 2002, 241(2):341-344.
  • 7Jacobs C, Kayser O, Muller R H. Production and characterization of mucoadhesive nanosuspensions for the formulation of bupravaquone[J]. Int J Pharm, 2001,214(5) :3-7.
  • 8Westesen K. Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof: US, 6207178[P]. 2001-02-15.
  • 9De Vringer. Topical preparation containing a suspension of solid lipid particles: US, 5904932[P]. 1999-08-22.
  • 10Friedrich I, Goymann C C M. Charactrization of solidified reverse micellar solutions (SRMS) and production development of SRMS-based nanosuspensions[J]. Eur J Pharm Biopharm,2003,56 (4): 111-119.

同被引文献47

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部